Sarabjit Kour Nangra

Rediff.com » News » Sarabjit Kour Nangra

News for Sarabjit Kour Nangra

Business

Indian firms eye $2.5-bn US drug market

Indian pharmaceutical majors are set to tap the generic anti-depressant market in the US, the largest pharma market in the world. The anti-depressant drug market in the US is primarily ruled by......

Investing? Look before you leap

While small-caps tend to outperform in a rising market, investors should watch for scrips riding on momentum rather than performance.With the broader indices continuing to power ahead and......

'Robust GDP, recovery to drive markets up'

The stock markets on Monday shrugged off the Dubai hiccups and ended the days almost two per cent higher, and analysts believe the momentum is likely to continue as the street will take positive......

Markets shrug off Lehman blues

Shrugging off the deadly blow received at the time of Lehman Brothers' collapse, stock markets in emerging countries, led by India, have moved significantly higher from the low levels witnessed a......

Generic drug makers target US patent mart

The increasing number of patent litigations in the US against Indian pharma companies and the emergence of patent challengers such as Sun Pharma, Lupin, Orchid and Glenmark are an indication that......

Web results for Sarabjit Kour Nangra

Street worries on Ranbaxy

Related to : Ranbaxy Laboratories Ltd Ranbaxy Laboratories Ltd BSE 22 May 13 | 12:00 AM 431.10 -5.25 (-1.2%) NSE 22 May 13 | 12:00 AM 431.05... ...

http://www.smartinvestor.in/market/Features-177341-Featuresdet-Street_worries_on_Ranbaxy.htm

After swallowing bitter pill, Ranbaxy set to revive sales in US

In an affirmative sign, Ranbaxy shrugged off early losses after Monday's ruling to steadily climb 1.75 percent to Rs 463.45 on Wednesday on the... ...

http://www.firstpost.com/business/after-swallowing-bitter-pill-ranbaxy-set-to-revive-sales-to-us-787055.html

US marketing to get tough for Ranbaxy Laboratories

Tags: Ranbaxy Laboratories | Arun Sawhney | Ranbaxy Atorvastatin | Sarabjit Kour Nangra | US Business Ranbaxy Laboratories may find it tough to... ...

http://www.financialexpress.com/news/us-marketing-to-get-tough-for-ranbaxy-laboratories/1115804

Ranbaxy to pop rebuild pill

Mumbai, May 14: The real challenge for Ranbaxy begins now after it admitted felony charges and agreed to pay $500 million to settle charges that it... ...

http://www.telegraphindia.com/1130515/jsp/business/story_16899873.jsp

...shares end nearly 4% higher.

Shares of Ranbaxy Laboratories recovered from early losses and settled nearly 4 per cent higher on hopes that settlement of its long lawsuit in the... ...

http://www.dailypioneer.com/business/shares-end-nearly-4-higher.html

See All

Rediff News

Sarabjit Kour Nangra

News for Sarabjit Kour Nangra

Indian firms eye $2.5-bn US drug market

Investing? Look before you leap

'Robust GDP, recovery to drive markets up'

Markets shrug off Lehman blues

Generic drug makers target US patent mart

Top Coverage News

Indian Premier League - IPL 2013

Coverage: The Match-Fixing Episode II - spot-fixing trial

Sachin Tendulkar : Cup of praise overfloweth - Reactions

Complete coverage of Mumbai blasts

Decoding India’s Corruption Wars - Ajit Balakrishnan's Blog